Lumexa Imaging Holdings SEC Filings

Lumexa Imaging Holdings, Inc. reported initial equity holdings for Chief Financial Officer Martin James Anthony. He beneficially holds two stock option awards, each covering 388,888 shares of common stock at an exercise price of $18.50 per share. One option vests in five substantially equal annual installments starting from January 1, 2025, conditioned on his continued service. The second option vests in three installments tied to stock price targets of $27.00, $36.00, and $45.00 per share, measured over any 60‑trading‑day volume weighted average price after a 180‑day lock‑up period, also requiring continued service. The filing notes it was submitted late due to delays obtaining EDGAR codes.

Lumexa Imaging Holdings, Inc. reported that its Chief Legal Officer and Corporate Secretary, Julie Szeker, submitted her resignation effective March 13, 2026. The company stated that her resignation is not due to any disagreement over operations, policies or practices and has begun a search for a successor.

Under a transition letter agreement, Ms. Szeker will receive a $450,000 transition payment and up to 12 months of subsidized healthcare coverage, subject to a release of claims and compliance with the agreement. She will also receive an annual bonus of $250,000 related to 2025 performance, payable at the same time as bonuses to other employees.

Lumexa Imaging Holdings, Inc. disclosed that its subsidiaries entered into an amended credit agreement led by Barclays Bank PLC. The agreement provides a secured term loan facility of $825 million maturing in December 2032 and a secured revolving credit facility of $250 million maturing in December 2030. Both facilities bear interest at the borrowers’ option at SOFR plus 3.00% or the Prime Rate plus 2.00%, with potential rate reductions on the revolver if certain senior secured net leverage ratios are met. The facilities are guaranteed by substantially all wholly owned subsidiaries and secured by substantially all of their assets, and include restrictive covenants and a financial covenant requiring a consolidated net leverage ratio not exceeding 7.50 to 1 if revolving borrowings exceed 40% of the revolver commitment at a quarter-end.

Lumexa Imaging Holdings, Inc. director filed an initial ownership report detailing derivative interests tied to the company’s common stock. The filing shows rights to receive 64,379 shares of common stock through Common Units of Lumexa Imaging Equity Holdco, LLC held directly, and an additional 91,256 shares indirectly through Charlotte Radiology Investors, LLC. Each nine Common Units correspond to one share of Lumexa Imaging’s common stock held by the LLC. After the IPO, Lumexa Imaging Equity Holdco, LLC may distribute its common shares to equity holders on a pro rata basis, but not before a 180-day lock-up period expires, and the director’s reported interests relate to shares that could be received in such a distribution.

Lumexa Imaging Holdings, Inc. reported that its Chief Executive Officer and director received two equity awards on December 12, 2025 totaling 129,728 restricted stock units (RSUs), each RSU representing one share of common stock. Each grant covers 64,864 RSUs at an acquisition price of $0 per share.

The first 64,864 RSUs vest in three substantially equal annual installments on each of the first three anniversaries of the grant date, subject to the executive’s continued service. The second 64,864 RSUs vest in three substantially equal installments upon achieving stock price targets of $27.00, $36.00 and $45.00 per share, based on 60‑trading‑day volume weighted average prices over measurement periods that can extend to the fourth anniversary of the grant, also requiring continued service.

Lumexa Imaging Holdings, Inc. reported that a director acquired 27,027 restricted stock units, each representing the contingent right to receive one share of the company’s common stock, on December 12, 2025 at a price of $0 per unit.

Following this grant, the reporting person is shown as beneficially owning 27,027 shares of common stock. The RSUs will vest annually in three substantially equal installments on each of the first three anniversaries of the grant date, subject to the reporting person’s continued service with the company.

Lumexa Imaging Holdings, Inc. reported that a company director acquired 27,027 shares of common stock on 12/12/2025 through a restricted stock unit grant at a price of $0 per share. Following this grant, the director beneficially owns 27,027 shares held directly.

The award consists of restricted stock units, each representing the contingent right to receive one share of common stock. Of these units, 13,513 vested on the grant date, and the remaining units are scheduled to vest in three substantially equal annual installments on each of the first three anniversaries of the grant date, subject to the director’s continued service with the company.

Lumexa Imaging Holdings, Inc. reported that its Chief Medical Officer, as an officer of the company, acquired a total of 8,464 restricted stock units (RSUs) representing shares of common stock on 12/12/2025 at a price of $0 per share, resulting in beneficial ownership of 8,464 shares held directly.

One grant of 4,232 RSUs vests annually in three substantially equal installments on each of the first three anniversaries of the grant date, subject to continued service. A second grant of 4,232 RSUs vests in three substantially equal installments upon reaching stock price targets of $27.00, $36.00 and $45.00 per share, measured by the volume weighted average closing price over any 60 consecutive trading days within a period that begins after a 180-day lock-up and runs to the three-year anniversary, with unachieved targets remaining eligible to vest through the four-year anniversary.

Lumexa Imaging Holdings, Inc. reported insider equity activity for its Chief Legal Officer and Corporate Secretary, Julie Szeker, dated December 12, 2025. A transaction coded “M” involved 1,250,000 incentive units of Lumexa Imaging Equity Holdco, LLC tied to 66,182 shares of common stock, which, according to the footnotes, had been converted into stock at the closing of the company’s initial public offering with replacement awards subject to time- and performance-based vesting conditions.

Following the reported activity, Szeker directly beneficially owned 147,263 shares of common stock, including 11,876 shares that vest only if the stock reaches a volume-weighted average price of $24.97 over a 60-trading-day period after the IPO lock-up expires, subject to continued service. She also holds 81,081 restricted stock units, each representing one share of common stock, scheduled to vest in full on December 12, 2026, provided she continues serving the company.